avenanthramides
Botanicalexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2015 (NCT02415374)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
NFKB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06101784 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2023 | Ceapro Inc., The Montreal Health Innovations Coordinating Center, University of Montreal |
| NCT02584946 | N/A | Mar 2, 2016 | PepsiCo, University of Minnesota |
| NCT02415374 | N/A | Jan 5, 2015 | PepsiCo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PepsiCo | For profit | 2 | 2 | 1 | 2015 |
| Ceapro Inc. | For profit | 1 | 0 | 1 | 2023 |
| The Montreal Health Innovations Coordinating Center | For profit | 1 | 0 | 1 | 2023 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Montreal | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1